Abstract
It was recently reported that the dosage of kanamycin formerly recommended for neonates of 7.5 mg/kg every 12 h did not produce therapeutic serum concentrations of 15 to 25 μg/ml, but a larger dosage of 10 mg/kg every 12 h was required. Reevaluation of the pharmacokinetics of kanamycin in infants and children was therefore undertaken. Sixteen time-concentration curves after a dose of 5 mg/kg were obtained from patients 2 months to 12 years of age; the mean peak serum kanamycin concentration was 10.9 (range, 3.6 to 17.9) μg/ml at 0.5 h. Ten time-concentration curves were obtained after a dose of 10 mg/kg; the mean peak serum concentration was 17.6 (range, 8.4 to 30) μg/ml. Eight patients were studied on successive days, and there was doubling of the 1-h peak serum concentration when the dose of kanamycin was increased from 5 to 10 mg/kg. Standard serum bactericidal tests were done against Escherichia coli and Enterobacter cloacae strains, each with a minimal bactericidal concentration of 5 μg of kanamycin per ml. All 3 sera containing 21 μg or more of kanamycin per ml demonstrated a bactericidal titer, whereas only 2 of 23 sera containing less than 21 μg of kanamycin per ml did so. The currently recommended dosage of kanamycin for infants and children fails to produce serum concentrations in the therapeutic range, and preliminary data suggest that the dosage should be increased to 10 mg/kg per dose every 8 h.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- BERGER S. H., WEHRLE P. F. Kanamycin serum levels in infants and children. Ann N Y Acad Sci. 1958 Sep 30;76(2):136–139. doi: 10.1111/j.1749-6632.1958.tb54700.x. [DOI] [PubMed] [Google Scholar]
- HIGH R. H., SARRIA A., HUANG N. N. Kanamycin in the treatment of infections in infants and children. Ann N Y Acad Sci. 1958 Sep 30;76(2):289–307. doi: 10.1111/j.1749-6632.1958.tb54719.x. [DOI] [PubMed] [Google Scholar]
- Howard J. B., McCracken G. H., Jr Reappraisal of kanamycin usage in neonates. J Pediatr. 1975 Jun;86(6):949–956. doi: 10.1016/s0022-3476(75)80234-4. [DOI] [PubMed] [Google Scholar]
- McCracken G. H., Jr Changing pattern of the antimicrobial susceptibilities of Escherichia coli in neonatal infections. J Pediatr. 1971 Jun;78(6):942–947. doi: 10.1016/s0022-3476(71)80422-5. [DOI] [PubMed] [Google Scholar]
- Simon H. J., Axline S. G. Clinical pharmacology of kanamycin in premature infants. Ann N Y Acad Sci. 1966 Jun 14;132(2):1020–1025. doi: 10.1111/j.1749-6632.1966.tb43028.x. [DOI] [PubMed] [Google Scholar]
- Simon H. J., Axline S. G. Clinical pharmacology of kanamycin in premature infants. Ann N Y Acad Sci. 1966 Jun 14;132(2):1020–1025. doi: 10.1111/j.1749-6632.1966.tb43028.x. [DOI] [PubMed] [Google Scholar]
- Simon H. J., Yin E. J. Microbioassay of antimicrobial agents. Appl Microbiol. 1970 Apr;19(4):573–579. doi: 10.1128/am.19.4.573-579.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- YOW M. D., TENGG N. E., BANGS J., BANGS T., STEPHENSON W. The ototoxic effects of kanamycin sulfate in infants and children. J Pediatr. 1962 Feb;60:230–242. doi: 10.1016/s0022-3476(62)80041-9. [DOI] [PubMed] [Google Scholar]
- van Rossum J. M. Pharmacokinetics of accumulation. J Pharm Sci. 1968 Dec;57(12):2162–2165. doi: 10.1002/jps.2600571230. [DOI] [PubMed] [Google Scholar]